In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
et al., Biochem. Biophys. Res. Comm., 323:1, 8 October 2004, doi:10.1016/j.bbrc.2004.08.085 (In Vitro)
, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem. Biophys. Res. Comm., 323:1, 8 October 2004, doi:10.1016/j.bbrc.2004.08.085 (In Vitro)
In Vitro study for SARS-CoV-1. IC50 of CQ for antiviral activity (8.8) is significantly lower than cytostatic activity CC50 (261.3), selectivity index of 30. IC50 for inhibition of SARS-CoV in vitro approximates the plasma concentrations of CQ reached during treatment of acute malaria. CQ may be considered for immediate use in the prevention and treatment of SARS-CoV infections.14 In Vitro studies support the efficacy of HCQ [Andreani, Clementi, Dang, Delandre, Faísca, Hoffmann, Liu, Ou, Purwati, Sheaff, Wang, Wang (B), Yao, Yuan].
1.
Andreani et al., Microbial Pathogenesis, doi:/10.1016/j.micpath.2020.104228,
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect,
https://www.sciencedirect.com/science/article/pii/S0882401020305155.
2.
Clementi et al., Front. Microbiol., 10 July 2020, doi:10.3389/fmicb.2020.01704 (preprint 3/31),
Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro,
https://www.frontiersin.org/articl..ign=ECO_FCIMB_XXXXXXXX_auto-dlvrit.
3.
Dang et al., bioRxiv, doi:10.1101/2021.03.16.435741,
Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein,
https://www.biorxiv.org/content/10.1101/2021.03.16.435741v1.
4.
Delandre et al., Pharmaceuticals, doi:10.3390/ph15040445,
Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants,
https://www.mdpi.com/1424-8247/15/4/445.
5.
Faísca et al., Pharmaceutics, doi:10.3390/pharmaceutics14040877,
Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2,
https://www.mdpi.com/1999-4923/14/4/877.
6.
Hoffmann et al., Nature, (2020), doi:10.1038/s41586-020-2575-3,
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2,
https://www.nature.com/articles/s41586-020-2575-3.
7.
Liu et al., Cell Discovery 6, 16 (2020), doi:10.1038/s41421-020-0156-0,
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro,
https://www.nature.com/articles/s41421-020-0156-0.
8.
Ou et al., PLOS Pathogens, doi:10.1371/journal.ppat.1009212 (preprint 7/22),
Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2,
https://journals.plos.org/plospath..le?id=10.1371/journal.ppat.1009212.
9.
Purwati et al., PLOS One, doi:10.1371/journal.pone.0252302,
An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia,
https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0252302.
10.
Sheaff, R., bioRxiv, doi:10.1101/2020.08.02.232892,
A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine Activity,
https://www.biorxiv.org/content/10.1101/2020.08.02.232892v1.
11.
Wang et al., Phytomedicine, doi:10.1016/j.phymed.2020.153333,
Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467095/.
12.
Wang (B) et al., Cell Res. 30, 269–271, doi:L10.1038/s41422-020-0282-0,
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,
https://www.nature.com/articles/s4..iVs8_7R1KkwOuqjRhx7psfHV6iSDRD1cM0.
13.
Yao et al., Clin. Infect. Dis., 2020 Mar 9, doi:10.1093/cid/ciaa237,
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
https://academic.oup.com/cid/advan..le/doi/10.1093/cid/ciaa237/5801998.
Keyaerts et al., 28 Aug 2004, peer-reviewed, 5 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2004.08.085
We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro. Chloroquine is a clinically approved drug effective against malaria. We tested chloroquine phosphate for its antiviral potential against SARS-CoV-induced cytopathicity in Vero E6 cell culture. Results indicate that the IC 50 of chloroquine for antiviral activity (8.8 ± 1.2 lM) was significantly lower than its cytostatic activity; CC 50 (261.3 ± 14.5 lM), yielding a selectivity index of 30. The IC 50 of chloroquine for inhibition of SARS-CoV in vitro approximates the plasma concentrations of chloroquine reached during treatment of acute malaria. Addition of chloroquine to infected cultures could be delayed for up to 5 h postinfection, without an important drop in antiviral activity. Chloroquine, an old antimalarial drug, may be considered for immediate use in the prevention and treatment of SARS-CoV infections.
References
Blau, Holmes, Human Coronavirus HCoV-229E enters susceptible cells via the endocytic pathway
Chan, Lai, Chu, Tsui, Tam et al., Treatment of severe acute respiratory syndrome with lopinavir/ ritonavir: a multicentre retrospective matched cohort study, Hong Kong Med. J
Charmot, Coulaud, Treatment of Plasmodium falciparum malaria in Africa (except cerebral malaria), Med. Trop
Chu, Cheng, Hung, Wong, Chan et al., HKU/UCH SARS study group, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax
Cinatl, Michaelis, Scholz, Doerr, Role of interferons in the treatment of severe acute respiratory syndrome, Expert, Opin. Biol. Ther
Cinatl, Morgenstern, Bauer, Chandra, Rabenau et al., Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus, Lancet
Drosten, Gunther, Preiser, Van Der Werf, Brodt et al., Identification of a novel coronavirus in patients with severe acute respiratory syndrome, N. Engl. J. Med
Fronhoffs, Totzke, Stier, Wernert, Rothe et al., A method for the rapid construction of cRNA standard curves in quantitative real-time reverse transcription polymerase chain reaction, Mol. Cell. Probes
Goodwin, Holt, Downes, Marshall, Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS, J. Immunol. Methods
Keyaerts, Vijgen, Chen, Maes, Hedenstierna et al., Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound, Int. J. Infect. Dis
Kouroumalis, Koskinas, Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report, Ann. Acad. Med. Singapore
Ksiazek, Erdman, Goldsmith, Zaki, Peret et al., SARS Working Group, A novel coronavirus associated with severe acute respiratory syndrome, N. Engl. J. Med
Kuiken, Fouchier, Schutten, Rimmelzwaan, Van Amerongen et al., Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome, Lancet
Marra, Jones, Astell, Holt, Brooks-Wilson et al., The genome sequence of the SARS-associated coronavirus, Science
Ng, Tan, See, Ooi, Ling, Proliferative growth of SARS coronavirus in Vero E6 cells, J. Gen. Virol
Pardridge, Yang, Diagne, Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes, Immunol. Lett
Pauwels, Balzarini, Baba, Snoeck, Schols et al., Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds, J. Virol. Methods
Peiris, Lai, Poon, Guan, Yam et al., Coronavirus as a possible cause of severe acute respiratory syndrome, Lancet
Rota, Oberste, Monroe, Nix, Campagnoli et al., Characterization of a novel coronavirus associated with severe acute respiratory syndrome, Science
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against todayÕs diseases?, Lancet Infect. Dis
Savarino, Gennero, Sperber, Boelaert, The anti-HIV-1 activity of chloroquine, J. Clin. Virol
Singh, Sidhu, Friedman, Maheshwari, Mechanism of enhancement of the antiviral action of interferon against herpes simplex virus-1 by chloroquine, J. Interferon Cytokine Res
Tsai, Nara, Kung, Oroszlan, Inhibition of human immunodeficiency virus infectivity by chloroquine, AIDS Res. Hum. Retroviruses
Wollheim, Hanson, Laurell, Chloroquine treatment in rheumatoid arthritis. Correlation of clinical response to plasma protein changes and chloroquine levels, Scand. J. Rheumatol
Wu, Jan, Chen, Hsieh, Hwang et al., Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide, Antimicrob. Agents Chemother
Yamamoto, Yang, Yoshinaka, Amari, Nakano et al., HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus, Biochem. Biophys. Res. Commun
Zhaori, Antiviral treatment of SARS: can we draw any conclusions?, CMAJ
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.